文献速递头颈外科

头颈癌出血的经动脉栓塞治疗:谁获益?

Transarterial Embolization for Bleeding in Patients with Head and Neck Cancer: Who Benefits?
PubMed 文献 · Laryngoscope · 2021-05-07

本研究回顾性纳入31例头颈癌相关不可控出血患者,共行40次急诊经动脉栓塞(TAE)。技术成功率100%,30天再出血率17.2%,中位生存263天。首次TAE时原发癌完全缓解是生存的显著影响因素。

要点

  • TAE对头颈癌相关出血技术成功率高,即使患者状态不稳定。
  • 颈动脉破裂综合征患者TAE后脑梗死风险需警惕。
  • 原发癌完全缓解者TAE后可能获得较长生存。

核心结论

  • TAE对头颈癌相关出血有效,即使患者状态不稳定。
  • 首次TAE时原发癌完全缓解的患者可获得较长生存。

研究设计与样本

  • 回顾性结局研究,纳入31例(27男4女,中位年龄61岁)头颈癌不可控出血患者。
  • 10年期间(2011年1月至2020年12月)共行40次急诊TAE,其中27例次状态不稳定,10例次为颈动脉破裂综合征。

主要发现

  • 技术成功率为100%。
  • 颈动脉破裂综合征患者中3例次出现脑梗死不良事件。
  • TAE后30天再出血率为17.2%,随访期(9-3004天)再出血率为35.5%。
  • 中位生存时间为263天(95%CI:124.0-402.0天)。
  • log-rank检验显示首次TAE时原发癌完全缓解是生存的显著影响因素。

临床怎么用

  • 对于头颈癌相关不可控出血,可考虑急诊TAE,即使患者状态不稳定。
  • 颈动脉破裂综合征患者行TAE时需警惕脑梗死风险。
  • 原发癌完全缓解的患者可能从TAE中获得较长生存。

局限性

  • 回顾性研究,样本量较小(31例患者,40次操作)。
  • 证据等级为4级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: The present study aimed to investigate the efficacy of transarterial embolization (TAE) for bleeding in patients with head and neck cancer (HNC) and to evaluate the prognostic factors after TAE. STUDY DESIGN: Outcome study. METHODS: This retrospective study included 31 consecutive patients (27 men and 4 women; median age, 61 years) who presented uncontrollable hemorrhage associated with HNC and underwent emergency TAE at our institution during a 10-year period (January 2011-December 2020). This corresponded to 40 TAE procedures, including 27 cases with an unstable status (circulatory and/or respiratory insufficiency) and 10 cases with carotid blowout syndrome. The technical success rate and adverse events were analyzed on a per-procedure basis. The rebleeding and overall survival (OS) rates were analyzed on a per-patient basis, and the factors related to OS were evaluated. RESULTS: The technical success rate was 100%. As an adverse event, cerebral infarction was found in three cases with carotid blowout syndrome. The rebleeding rate at 30 days after TAE and in the follow-up period (range, 9-3,004 days) was 17.2% and 35.5%, respectively. The median survival time was 263 days (95% confidence interval: 124.0-402.0 days). In the log-rank test, complete remission (CR) of the primary cancer at the time of the first TAE was identified as a significant influencing factor of survival. CONCLUSION: TAE is effective for the treatment of hemorrhage associated with HNC even in patients with an unstable status. Patients with CR can gain a long life span. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E2777-E2783, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Chatani S, Sato Y, Murata S, et al. Transarterial Embolization for Bleeding in Patients with Head and Neck Cancer: Who Benefits? Laryngoscope. 2021. PMID: 33960405. doi:10.1002/lary.29611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。